HC Wainwright restated their buy rating on shares of Obseva (NASDAQ:OBSV) in a report published on Monday, May 6th, AnalystRatings.com reports.
“We feel that this long-term durability of effect should bode well for the future of linzagolix in endometriosis. In anticipation of further progress in 2019 with linzagolix, nolasiban and OBE022, we reiterate our Buy rating and 12-month target of $44 per share. Bone mineral density appears to be reverting to baseline. Changes in bone mineral density (BMD) from baseline to week 52—measured by dual-energy x-ray absorptiometry (DXA) scan—were consistent with the values observed at 24 weeks of treatment. In our view, these data—along with the pain relief efficacy observed long-term—further support the dose selection for the Phase 3 program in women with endometriosis-associated pain (i.e., linzagolix 75mg once-daily dose without add- back hormonal therapy (ABT), and 200mg once-daily dose in combination with low-dose ABT).”,” HC Wainwright’s analyst commented.
OBSV has been the topic of several other research reports. Wedbush set a $34.00 target price on shares of Obseva and gave the stock a buy rating in a research report on Friday, January 25th. TheStreet cut shares of Obseva from a c- rating to a d+ rating in a report on Wednesday, January 16th. Zacks Investment Research cut shares of Obseva from a hold rating to a sell rating in a report on Wednesday, March 6th. Finally, ValuEngine cut shares of Obseva from a buy rating to a hold rating in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $29.14.
Obseva (NASDAQ:OBSV) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.09). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. As a group, equities analysts forecast that Obseva will post -2.27 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in Obseva by 14.2% during the first quarter. Renaissance Technologies LLC now owns 74,000 shares of the company’s stock valued at $946,000 after acquiring an additional 9,200 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Obseva by 92.1% during the first quarter. Dimensional Fund Advisors LP now owns 135,547 shares of the company’s stock valued at $1,734,000 after acquiring an additional 64,974 shares in the last quarter. Wells Fargo & Company MN grew its stake in Obseva by 25.3% during the first quarter. Wells Fargo & Company MN now owns 4,953 shares of the company’s stock valued at $63,000 after acquiring an additional 1,000 shares in the last quarter. Fosun International Ltd purchased a new position in Obseva during the first quarter valued at $2,494,000. Finally, JPMorgan Chase & Co. grew its stake in Obseva by 159.2% during the first quarter. JPMorgan Chase & Co. now owns 24,482 shares of the company’s stock valued at $313,000 after acquiring an additional 15,037 shares in the last quarter. 63.58% of the stock is owned by hedge funds and other institutional investors.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: The risks of owning bonds
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.